Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
32472
CAS Number:
78287-27-1
7-Éthylcamptothécine
Purity:
≥ 99 % (HPLC)
Synonym(s):
(4 S )-4,11-diéthyl-4-hydroxy-1 H -pyrano[3',4':6,7]indolizino[1,2-b]quinoléine-3,14(4 H ,12 H )-dione
Hazmat
Documents
$51.18 /250 mg
Taille
Request Bulk Quote
Informations sur le produit

Conserver le récipient bien fermé dans un endroit sec et bien aéré.

Numéro CAS 
78287-27-1
Formule moléculaire
C22H20N2O4
Poids moléculaire 
0
Point de fusion 
258 - 260 °C (déc.)
Rotation optique 
[a]20/D= 40 à 46 ° (C=0,4 dans CHCl3:MeOH=8:2)
Informations générales
Numéro CAS 
78287-27-1
Formule moléculaire
C22H20N2O4
Poids moléculaire 
0
Point de fusion 
258 - 260 °C (déc.)
Rotation optique 
[a]20/D= 40 à 46 ° (C=0,4 dans CHCl3:MeOH=8:2)
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

7-Ethylcamptothecin is widely utilized in research focused on:

  • Cancer Treatment: This compound is a potent inhibitor of topoisomerase I, making it a valuable candidate in the development of anti-cancer therapies. It has shown promising results in clinical trials for various cancers, including colorectal and lung cancer.
  • Pharmaceutical Development: Researchers are exploring its potential in formulating new drugs that can overcome resistance seen with traditional chemotherapy agents. Its unique structure allows for modifications that can enhance efficacy and reduce side effects.
  • Drug Delivery Systems: Due to its hydrophobic nature, 7-Ethylcamptothecin can be incorporated into nanocarriers for targeted drug delivery, improving the concentration of the drug at tumor sites while minimizing systemic exposure.
  • Research on Mechanisms of Action: Scientists use this compound to study the mechanisms of DNA damage and repair, providing insights into cellular responses to chemotherapy and helping to identify biomarkers for treatment efficacy.
  • Combination Therapies: It is being investigated in combination with other therapeutic agents to enhance overall treatment outcomes, particularly in resistant cancer types, showcasing its versatility in oncology.

Citations